From July 19, 2024 until July 20, 2024
At Munich - Holiday Inn Munich - City Centre, Bavaria, Germany
Posted by Canton Fair Net
https://www.esmo.org/meeting-calendar/esmo-congress-2023
Categories: Healthcare and Pharmaceuticals
Hits: 1832
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
You're using an older version of your web browser, so some features may not display properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 improves rPFS for metastatic castration resistant prostate cancer patients who are taxane-naive23 Oct 2023The PSMAfore trial's findings are limited by the fact that they do not show a benefit in terms of OS.